Ohana Bio Adds Ramiro Castro-Santamaria as Chief Medical Officer

Ohana Biosciences announced it appointed Ramiro Castro-Santamaria, a urologist and family medicine physician, as its chief medical officer. Castro-Santamaria was most recently vice president of clinical sciences and head of rheumatology at GlaxoSmithKline (NYSE: [[ticker:GSK]]), where he spent 14 years serving in various clinical development and R&D roles. His prior experience includes roles at Boehringer Ingelheim and at Pharmacia, later acquired by Pfizer (NYSE: [[ticker:PFE]]).

The Cambridge, MA-based biotech, which spun out from Flagship Pioneering this year, is advancing fertility and contraceptive programs based on its research into sperm biology. Its CEO, Amber Salzman, is also a former GlaxoSmithKline executive.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine. View all posts by Sarah de Crescenzo